Skip to main content

Table 1 Clinical trials for platinum-based chemotherapy in ovarian cancer

From: Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer

Characteristic Cancer Treatment regimen Patients enrolled PFS(mo) OS(mo)
Stage III and Stage IV [7] Ovarian Cisplatin (75 mg per square meter of body-surface area)
Cyclophosphamide (750 mg per square meter)
202 13 24
Cisplatin (75 mg per square meter of body-surface area)
Paclitaxel (135 mg per square meter over a period of 24 h).
184 18 38
Stage III and Stage IV [8]
(NCT02655016)
Ovarian Niraparib once daily after a response to platinum-based chemotherapy. 487 13.9 84% (24-month interim analysis)
Placebo group once daily after a response to platinum-based chemotherapy 246 8.2 77% (24-month interim analysis)
Relapsed > 6 months following completion of platinum-based therapy [9]
(NCT00083122)
Ovarian and Primary Peritoneal Carcinoma Cisplatin (60 mg/m2 IV) Flavopiridol (100 mg/m2 IV, 24 h infusion; 21 day cycles) 40 4.3 16.1